文献速递药物不良反应与药物警戒

CAR-T细胞疗法上市后安全性监测:FAERS数据库分析

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
PubMed 文献 · Drug Saf · 2022-07-12

基于FAERS数据库(2017年10月至2020年9月)对tisagenlecleucel和axicabtagene ciloleucel的上市后安全性进行分析,共识别3225份报告。细胞因子释放综合征(52.2%)、发热性疾病(27.7%)和神经毒性(27.2%)最常见,75%事件发生于前10天。不相称性分析确认已知不良反应并发现潜在新信号,如axi-cel与心肌病、胃肠道穿孔,tisa-cel与肝毒性、瞳孔障碍。

要点

  • 细胞因子释放综合征和神经毒性常共同报告,75%事件发生于治疗前10天。
  • axi-cel显示心肌病和胃肠道穿孔的不相称信号,tisa-cel显示肝毒性和瞳孔障碍信号。
  • tisa-cel可能与免疫缺陷相关事件(低丙种球蛋白血症、感染)和凝血病相关,axi-cel与神经毒性相关。

核心结论

  • 本研究确认了CAR-T细胞疗法已知的不良反应,并检测到每种疗法特有的潜在新安全性问题。

研究设计与样本

  • 基于FDA不良事件报告系统(FAERS)的上市后监测研究,查询2017年10月至2020年9月数据,分析tisagenlecleucel和axicabtagene ciloleucel的疑似不良反应。
  • 共识别3225份报告(axi-cel 1793份;tisa-cel 1433份),采用报告比值比进行不相称性分析,设置三个参照组。

主要发现

  • 报告毒性主要为细胞因子释放综合征(52.2%)、发热性疾病(27.7%)和神经毒性(27.2%)。
  • 细胞因子释放综合征和神经毒性常共同报告,75%的事件发生于前10天。
  • axi-cel与心肌病报告比值比=2.3(95%CI 1.2-4.4)、胃肠道穿孔(2.9;1.2-7.3)存在不相称性。
  • tisa-cel与肝毒性(2.5;1.1-5.7)和瞳孔障碍(15.3;6-39.1)存在不相称性。

临床怎么用

  • 临床应关注CAR-T治疗后前10天的细胞因子释放综合征和神经毒性监测。
  • 使用axi-cel时需警惕心肌病和胃肠道穿孔风险,使用tisa-cel时需关注肝毒性和瞳孔障碍。
  • tisa-cel治疗患者应监测免疫缺陷相关事件(如低丙种球蛋白血症、感染)和凝血病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: As chimeric antigen receptor T-cell therapies are becoming increasingly available in the armamentarium of the hematologist, there is an emerging need to monitor post-marketing safety. OBJECTIVE: We aimed to better characterize their safety profile by focusing on cytokine release syndrome and identifying emerging signals. METHODS: We queried the US Food and Drug Administration Adverse Event Reporting System (October 2017-September 2020) to analyze suspected adverse drug reactions to tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel). Disproportionality analyses (reporting odds ratio) were performed by comparing chimeric antigen receptor T-cell therapies with (a) all other drugs (reference group 1) and (b) other onco-hematological drugs with a similar indication, irrespective of age (reference group 2), or (c) restricted to adults (reference group 3). Notoriety was assessed through package inserts and risk management plans. Adverse drug reaction time to onset and cytokine release syndrome features were investigated. RESULTS: Overall, 3225 reports (1793 axi-cel; 1433 tisa-cel) were identified. The reported toxicities were mainly: cytokine release syndrome (52.2%), febrile disorders (27.7%), and neurotoxicity (27.2%). Cytokine release syndrome and neurotoxicity were often co-reported and 75% of the events occurred in the first 10 days. Disproportionalities confirmed known adverse drug reactions and showed unexpected associations: for example, axi-cel with cardiomyopathies (reporting odds ratio = 2.3; 95% confidence interval 1.2-4.4) and gastrointestinal perforations (2.9; 1.2-7.3), tisa-cel with hepatotoxicity (2.5; 1.1-5.7) and pupil disorders (15.3; 6-39.1). CONCLUSIONS: Our study confirms the well-known adverse drug reactions and detects potentially emerging safety issues specific for each chimeric antigen receptor T-cell therapy, also providing insights into a stronger role for tisa-cel in inducing some immunodeficiency-related events (e.g., hypogammaglobulinemia, infections) and coagulopathies, and for axi-cel in neurotoxicity.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Fusaroli M, Isgrò V, Cutroneo PM, et al. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database. Drug Saf. 2022. PMID: 35829913. doi:10.1007/s40264-022-01194-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。